PARKINSON'S disease symptoms have been positively affected by diabetes medication exenatide, marketed in Australia by AstraZeneca as Bydureon and Byetta, in a new UK study.
"Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain," researchers concluded, but expressed confidence that "exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials".
The research was funded by the Michael J Fox Foundation for Parkinson's Research.
Visit thelancet.com for the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 17